Most Recent
Pharmaceutical giant Pfizer has fired off a lawsuit against four drug companies for allegedly infringing one of its patents for biologic Enbrel by selling a biosimilar of the blockbuster arthritis drug in Australia.
Bayer has dropped its appeal to a ruling that quashed an extension for its patent covering an oral contraceptive, after the Full Court dealt drug makers a blow in two separate cases on how patent term extensions should be calculated.
Apple is “unlikely” to avoid production of the source code for its Touch ID and Face ID technology to an Australian non-practicing entity that has sued the Silicon Valley company for patent infringement, a judge has said.
The Full Court has overturned a landmark judgment which found artificial intelligence can be named as an inventor on patent applications, in a decision which brings Australia in line with findings from courts in the UK, US and EU.
Car repair giant AMA Group may have a discovery fight on its hands in its lawsuit against former boss Andrew Hopkins for allegedly defrauding the company of $3 million.
Maurice Blackburn has successfully defeated an appeal of a judgment that found the law firm did not breach the intellectual property rights of US financial services giant State Street Global Advisors by displaying a replica of the world renowned Fearless Girl statue in Melbourne.
The Full Federal Court won't give Swiss pharmaceuticals giant Novartis the chance to appeal a ruling that threw out three of its four experts in a patent case against generic drug maker Pharmacor.
Novartis wants to appeal a ruling in its dispute with generic drug maker Pharmacor over patents for its multiple sclerosis drug Gilenya that tossed three of its four experts out of an upcoming so-called hot tub.
A judge has questioned GME’s pursuit of additional damages in its intellectual property lawsuit against Japan’s Uniden that alleges the upcoming launch by the wireless communication giant of two new CB radio products amounts to infringement of its design patent.
The Full Court has upheld two judgments that shortened patent term extensions granted to Merck Sharpe & Dohme and Ono Pharmaceuticals, finding the extension regime cannot be construed as achieving a "commercial outcome for a patentee".